Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading on Thursday. $92.99 million flowed into the stock on the tick-up and $139.79 million flowed out of the stock on the tick-down, for a money net flow of $46.80 million out of the stock. Of all equities tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $1.69 for the day and closed at $70.33
GILD has been the subject of several research analyst reports. BidaskClub downgraded shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 20th. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday. Barclays reduced their target price on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 2nd. Leerink Swann set a $72.00 target price on shares of Gilead Sciences and gave the stock a “market perform” rating in a report on Wednesday, May 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, fifteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $88.22.
The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84. The firm has a market cap of $91.45 billion, a PE ratio of 8.28, a PEG ratio of -6.12 and a beta of 1.15.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the prior year, the firm earned $2.23 EPS. The business’s revenue for the quarter was down 21.8% on a year-over-year basis. equities analysts anticipate that Gilead Sciences, Inc. will post 5.75 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, June 28th. Stockholders of record on Friday, June 15th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.22%. The ex-dividend date of this dividend was Thursday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
In other news, Director John Francis Cogan sold 5,836 shares of the company’s stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of $65.09, for a total transaction of $379,865.24. Following the completion of the sale, the director now owns 58,455 shares of the company’s stock, valued at approximately $3,804,835.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $73.14, for a total transaction of $3,657,000.00. Following the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $224,376,112.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 179,168 shares of company stock valued at $12,789,233. 1.30% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. Archford Capital Strategies LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $106,000. Advisors Preferred LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $140,000. Stelac Advisory Services LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $141,000. Certified Advisory Corp bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $133,000. Finally, Mckinley Capital Management LLC Delaware lifted its holdings in shares of Gilead Sciences by 67.7% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 860 shares during the period. 77.65% of the stock is owned by institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.